Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HAILEY 1.5/30 vs ADQUEY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive containing ethinyl estradiol and desogestrel. Ethinyl estradiol suppresses gonadotropin release via negative feedback on the hypothalamic-pituitary axis; desogestrel, a progestin, inhibits ovulation and alters cervical mucus and endometrial receptivity.
ADQUEY (aducanumab) is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, reducing Aβ plaques in the brain. The exact mechanism linking Aβ reduction to clinical improvement is not fully established.
Prevention of pregnancy
Alzheimer disease (FDA approved for treatment of mild cognitive impairment or mild dementia stage),Off-label: none established
One tablet (ethinyl estradiol 0.03 mg, levonorgestrel 0.15 mg) orally once daily at the same time each day for 21 days, followed by 7 placebo tablets. For continuous cycling, may take active tablets daily without placebo.
400 mg orally once daily with food.
Terminal elimination half-life of ethinyl estradiol is 13-27 hours (mean 17 hours); for norgestimate, active metabolite norelgestromin has half-life 12-30 hours (mean 19 hours). Steady state reached after 7-14 days.
Terminal half-life 12-15 hours; prolonged in renal impairment (up to 30 hours in Cr Cl <30 m L/min)
Ethinyl estradiol undergoes hepatic metabolism primarily via CYP3A4; desogestrel is rapidly metabolized to its active metabolite etonogestrel via hydroxylation and dehydrogenation, further metabolized via CYP2C9 and CYP3A4.
Metabolized via catabolic pathways similar to endogenous Ig G; no specific cytochrome P450 enzyme involvement.
Approximately 40% renal (as metabolites), 32% fecal (as metabolites), and <1% unchanged in urine.
Renal: 70-80% unchanged; Fecal: 5-10% as metabolites; Biliary: minimal (<2%)
Ethinyl estradiol: ~98% bound to albumin; norelgestromin: ~99% bound to albumin and SHBG.
98% bound to albumin
Ethinyl estradiol: 2.3-4.0 L/kg; norelgestromin: 2.0-3.5 L/kg. Indicates extensive tissue distribution.
0.2-0.3 L/kg; indicates limited extravascular distribution
Oral: Ethinyl estradiol 40-55% (first-pass metabolism); norelgestromin: ~80% (as metabolite of norgestimate).
Oral: 85-90%; IM: 95-100%
No dose adjustment required for mild to moderate renal impairment. Not studied in severe impairment, but estrogen metabolites may accumulate; use caution.
Cr Cl ≥60 m L/min: no adjustment; Cr Cl 30-59 m L/min: 200 mg daily; Cr Cl <30 m L/min: 100 mg daily; hemodialysis: 100 mg daily after dialysis.
Contraindicated in acute liver disease or severe hepatic impairment (Child-Pugh C). For mild to moderate (Child-Pugh A or B), use is not recommended due to altered hormone clearance; if used, monitor liver function and consider lower estrogen dose.
Child-Pugh A: no adjustment; Child-Pugh B: 200 mg daily; Child-Pugh C: not recommended.
Postmenarchal adolescents: Same adult dosing (one tablet daily). Safety and efficacy not established in premenarchal girls.
Weight ≥10 kg: 12 mg/kg/dose twice daily; weight <10 kg: 8 mg/kg/dose twice daily.
Not indicated for postmenopausal women; contraindicated after menopause due to increased risk of cardiovascular events. No specific geriatric dose.
Initial dose 200 mg daily; titrate based on renal function; monitor for neuropsychiatric effects.
Cigarette smoking increases the risk of serious cardiovascular side effects from combination oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use combination oral contraceptives should be strongly advised not to smoke.
Amyloid-related imaging abnormalities (ARIA), including ARIA-E (edema/effusion) and ARIA-H (hemosiderin deposition), can occur. ARIA is usually asymptomatic but serious events including seizure and status epilepticus have been reported. Patients with apolipoprotein E ε4 homozygosity have a higher incidence of ARIA.
Increased risk of thromboembolic disorders,Cigarette smoking increases cardiovascular risk,Elevated blood pressure,Gallbladder disease,Hepatic neoplasia,Carbohydrate and lipid effects,Ocular lesions,Headache/migraine,Bleeding irregularities,Depression
1) Amyloid-related imaging abnormalities (ARIA): monitor with MRI before and during treatment; consider dose interruption or discontinuation if severe. 2) Hypersensitivity reactions: angioedema, urticaria reported. 3) Risk of falls due to cognitive impairment. 4) No head-to-head trials showing superiority over other treatments.
Active or history of venous thromboembolism,Cerebrovascular disease,Coronary artery disease,Valvular heart disease with complications,Thrombogenic valvulopathies,Major surgery with prolonged immobilization,Diabetes with vascular involvement,Uncontrolled hypertension,Active liver disease,Known or suspected pregnancy,Breast cancer or other estrogen-sensitive neoplasia,Heavy smoking (≥15 cigarettes/day) and age ≥35
History of severe hypersensitivity to aducanumab or any excipients in ADQUEY.
No significant food interactions. Grapefruit juice may slightly increase estrogen levels but not clinically relevant. A high-fat meal may delay absorption but does not reduce efficacy. Avoid excessive alcohol as it may increase liver enzymes and theoretically reduce efficacy.
Avoid grapefruit and grapefruit juice; may increase drug levels. High-fat meals can increase absorption; take with food or on an empty stomach consistently.
FDA Pregnancy Category X. Combined hormonal contraceptives (CHCs) are contraindicated in pregnancy. First trimester exposure is associated with a low risk of fetal malformations; however, CHCs should be discontinued if pregnancy occurs. Second and third trimester exposure may increase risks of fetal adverse outcomes, including but not limited to congenital anomalies and fetal demise. Use is not recommended at any trimester.
ADQUEY (estradiol valerate/dienogest) is contraindicated in pregnancy. First trimester exposure may cause congenital anomalies including cardiovascular and neural tube defects. Second and third trimester exposure may lead to feminization of male fetuses and other adverse outcomes.
CHCs may reduce milk production and composition. Small amounts of synthetic estrogen and progestin are excreted in breast milk. M/P ratio not specifically reported for this combination; ethinyl estradiol M/P ratio approximately 0.02-0.05. Use during lactation is generally not recommended, especially in early postpartum period. Alternative contraception should be considered.
Excretion into breast milk is minimal; however, ADQUEY may reduce milk production and quality. M/P ratio not established. Avoid use during breastfeeding.
Contraindicated in pregnancy; no dose adjustments applicable as drug should be discontinued immediately upon confirmed pregnancy. Pharmacokinetic changes during pregnancy (e.g., increased clearance) are not relevant given contraindication.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue immediately if pregnancy occurs.
HAILEY 1.5/30 is a combination oral contraceptive containing ethinyl estradiol 30 mcg and levonorgestrel 1.5 mg. It is a monophasic pill with 21 active tablets. Counsel patients that missed pills increase pregnancy risk, especially if more than one active pill is missed. Use back-up contraception for 7 days if a dose is missed. Consider increased risk of venous thromboembolism (VTE) in smokers over 35, obese patients, or those with thrombophilia. Nausea may be reduced by taking with food or at bedtime. Spotting is common in first 3 cycles; if persistent, rule out pregnancy or other causes.
Administration with a full glass of water and staying upright for 30 minutes reduces risk of esophagitis. Monitor for cutaneous lupus erythematosus and Stevens-Johnson syndrome. Avoid concomitant use with drugs that prolong QT interval due to risk of torsades de pointes.
Take one pill daily at the same time for 21 days, then 7 placebo pills.,If you miss a pill, follow the package insert instructions for missed doses and use back-up contraception (e.g., condoms) for 7 days.,Do not smoke while taking this medication, especially if over age 35, due to increased risk of blood clots.,Common side effects include nausea, breast tenderness, and spotting, which usually improve after 3 cycles.,Seek immediate medical attention for symptoms of blood clots: sudden leg pain/swelling, chest pain, shortness of breath, or severe headache.,Antibiotics (except rifampin) do not reduce effectiveness; however, certain drugs like rifampin, griseofulvin, and some anticonvulsants may decrease efficacy.,Store at room temperature, away from moisture and heat.
Take exactly as prescribed; do not double doses if missed.,Swallow tablet whole; do not crush or chew.,Avoid direct sunlight; use sunscreen and protective clothing.,Report any skin rash, blisters, or eye irritation immediately.,Do not take with antacids, iron supplements, or sucralfate; separate by at least 4 hours.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HAILEY 1.5/30 vs ADQUEY, answered by our medical review team.
HAILEY 1.5/30 is a Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and desogestrel. Ethinyl estradiol suppresses gonadotropin release via negative feedback on the hypothalamic-pituitary axis; desogestrel, a progestin, inhibits ovulation and alters cervical mucus and endometrial receptivity.. ADQUEY is a Oral Contraceptive that works by ADQUEY (aducanumab) is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, reducing Aβ plaques in the brain. The exact mechanism linking Aβ reduction to clinical improvement is not fully established.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HAILEY 1.5/30 and ADQUEY depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HAILEY 1.5/30 is: One tablet (ethinyl estradiol 0.03 mg, levonorgestrel 0.15 mg) orally once daily at the same time each day for 21 days, followed by 7 placebo tablets. For continuous cycling, may take active tablets daily without placebo.. The standard adult dose of ADQUEY is: 400 mg orally once daily with food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HAILEY 1.5/30 and ADQUEY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HAILEY 1.5/30 is classified as Category C. FDA Pregnancy Category X. Combined hormonal contraceptives (CHCs) are contraindicated in pregnancy. First trimester exposure is associated with a low risk of fetal malformations; h. ADQUEY is classified as Category C. ADQUEY (estradiol valerate/dienogest) is contraindicated in pregnancy. First trimester exposure may cause congenital anomalies including cardiovascular and neural tube defects. Sec. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.